Suppressive Molecules of Diseases with Altered IgE Regulation

Suppressive Molecules of Diseases with Altered IgE Regulation Background: Previous research has demonstrated that congeners of tetracycline, minocycline, and doxycycline suppress asthmatic symptoms in vivo, and immunoglobulin E (IgE) from asthmatics in vitro in a dose-dependent manner. In theory, the active site(s) responsible for suppression of these congeners include (but are not limited to) mono-, di-, and tri-cyclic components. These molecules, and similar derivatives, can be modified as needed to achieve maximum suppressive effect. Technology Overview: This technology from SUNY Downstate Health Sciences University consists of small molecular active fragments derived from molecules known to have suppressive effects in diseases with altered IgE regulation. These molecules can be used in the treatment of diseases/disorders such as allergies, asthma, and others, without the side effects generally associated with commonly used anti-inflammatories such as corticosteroids and other agents. As a result, this technology provides a new approach to the development of more effective treatments for patients suffering from diseases associated with abnormal IgE regulation. Advantages: Applications: Intellectual Property Summary: Patented Stage of Development: Mono di & tri cyclic compounds useful for lowering IgE concentrations – US 7.425,655 B2 filed 2/9/04 Mono, di and tri cyclic compounds useful for lowering IgE concentrations – US 7,649,113 B2 filed 8/25/08 Licensing Potential: Licensing Licensing Status: This technology is available for licensing and will be of value to any company or institution involved in developing treatments for diseases/disorders associated with IgE regulation, such as allergies and asthma. This includes: – Pharmaceutical companies – Research facilities – Hospitals Additional Information: ige,immunoglobulin,active site,asthma,side effect,anti-inflammatory,inflammatory,pharmaceutical,rare disease,rare diseases,small molecules,small molecule,small-molecule,allergy treatment,allergy relief,allergy medicine,asthma management,asthma treatment,allergic asthma,asthma control


Contact Information

TTO Home Page:

Name: Andrew Scheinman

Title: Business Development & Licensing Associate

Department: Industry & External Partnerships